Crucell Holland BV clinical trials

Acquired by Johnson & Johnson, Feb 22, 2011 · source ↗

The registry lists 37 studies whose lead sponsor is Crucell Holland BV. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 22, 2025.

Studies

Recruiting first, then most recently updated. Showing 37 of 37. All Johnson & Johnson studies →

• A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsCompletedNCT02543268Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza ChallengeCompletedNCT01938352Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR VaccinesCompletedNCT01307436Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected AdultsCompletedNCT02218125Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult ParticipantsCompletedNCT02440035Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedNCT02313077Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedNCT02376426Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedNCT02376400Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult VolunteersCompletedNCT02561871Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult VolunteersCompletedNCT02304185Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy AdultsCompletedNCT02148328Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza PatientsCompletedNCT01839760

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Clinical Study for Safety and Immunogenicity Study of Influenza VaccineCompletedNCT01617239Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A VaccineCompletedNCT01405677Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and UnijectCompletedNCT01917357Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza InfectionWithdrawnNCT01992276Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in NewbornsCompletedNCT01349283Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young ChildrenCompletedNCT01310400Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal VCompletedNCT01229397Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted before Crucell Holland BV became part of Johnson & Johnson

• Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza StrainsCompletedNCT01631110Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza StrainsCompletedNCT01631071Not applicable

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Assessment of CR8020, a Monoclonal Antibody Against Influenza A VirusesCompletedNCT01756950Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Assessment of CR6261, a Monoclonal Antibody Against the Influenza A VirusCompletedNCT01406418Phase 1

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young ChildrenCompletedNCT01349829Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood VaccinationCompletedNCT01357720Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different SuppliersCompletedNCT01412281Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern HemisphereCompletedNCT01303510Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two SuppliersCompletedNCT01229371Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted before Crucell Holland BV became part of Johnson & Johnson

• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306305Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306253Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)CompletedNCT01893177Phase 3

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01228383Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted before Crucell Holland BV became part of Johnson & Johnson

• A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza SeasonCompletedNCT01457027Phase 4

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge ModelCompletedNCT01397227Phase 1/2

  Sponsor listed in the registry: Crucell Holland BV · First submitted after Crucell Holland BV became part of Johnson & Johnson

• Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and AdolescentsCompletedNCT00708084Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted before Crucell Holland BV became part of Johnson & Johnson

• A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult SubjectsCompletedNCT00656097Phase 2

  Sponsor listed in the registry: Crucell Holland BV · First submitted before Crucell Holland BV became part of Johnson & Johnson